'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

2:21Policeisonthesceneofamassshootingincidentat800blockofGretnaCourtintheSouthernDistrict,inBaltimor ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri




focus

author：comprehensive    Page View：5193
Alastair Grant/AP

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

advertisement

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope